Format

Send to

Choose Destination
Clin Orthop Relat Res. 2011 Sep;469(9):2531-7. doi: 10.1007/s11999-010-1685-x.

Is reverse shoulder arthroplasty a reasonable alternative for revision arthroplasty?

Author information

1
The Rothman Institute of Orthopaedics at Thomas Jefferson University Hospital, 925 Chestnut Street, 5th Floor, Philadelphia, PA 19107, USA.

Abstract

BACKGROUND:

Reverse shoulder arthroplasty (RSA) improves function in selected patients with complex shoulder problems. However, we presume patient function would vary if performed primarily or for revision and would vary with other patient-specific factors.

QUESTIONS/PURPOSES:

We compared (1) the shoulder scores and (2) complications in patients with RSA for revision arthroplasty with patients who had RSA as a primary procedure; and (3) identified patient-specific factors that affect (1) and (2).

PATIENTS AND METHODS:

We retrospectively compared 28 RSAs for failed arthroplasty with a control group consisting of 28 primary RSAs. We determined the Penn Shoulder (PENN), American Shoulder and Elbow Surgeons (ASES), and Single Assessment Numeric Evaluation (SANE) scores. Followup for shoulder outcome measures averaged 17.4 (range, 4.1-34) and 20.8 months (range, 7.3-34.9) for the study and control groups, respectively.

RESULTS:

All scores were higher in primary RSA than in revision RSA (PENN score, 79.5 versus 57.1; ASES score, 81.4 versus 56.3; SANE score, 73.8% versus 48.8%), and ROM was better (122.7° versus 83.75°). Both groups experienced increases in active forward flexion. Ten of the 28 study RSAs (35.7%) versus five of the 28 control RSAs (17.8%) had complications. No patient-specific factors other than reason for surgery correlated with scores.

CONCLUSIONS:

Revision RSA is associated with lower function compared with primary RSA. However, we believe it a reasonable alternative and patients undergoing RSA for revision arthroplasty can expect improvements in function and shoulder scores to a mean of 50% of normal shoulders but must also accept a high complication rate.

LEVEL OF EVIDENCE:

Level III, therapeutic study. See the Guidelines for Authors for a complete description of levels of evidence.

PMID:
21116757
PMCID:
PMC3148363
DOI:
10.1007/s11999-010-1685-x
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Wolters Kluwer Icon for PubMed Central
Loading ...
Support Center